{"id":"carbo-5fu-cetuximab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hand-foot syndrome"},{"rate":"10-30%","effect":"Rash"},{"rate":"10-20%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Carbo (capecitabine) is a prodrug that is converted into 5-fluorouracil (5FU), which is a thymidylate synthase inhibitor. 5FU interferes with DNA synthesis, causing cell death in rapidly dividing cancer cells. Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), preventing it from promoting cell proliferation and survival.","oneSentence":"Carbo, 5FU, and Cetuximab work together to inhibit DNA synthesis and induce apoptosis in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:08.386Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT01864772","phase":"PHASE2","title":"Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2013-09","conditions":"Metastatic or Recurrent Head and Neck Squamous Cell Cancer","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Carbo, 5FU, Cetuximab","genericName":"Carbo, 5FU, Cetuximab","companyName":"Groupe Oncologie Radiotherapie Tete et Cou","companyId":"groupe-oncologie-radiotherapie-tete-et-cou","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carbo, 5FU, and Cetuximab work together to inhibit DNA synthesis and induce apoptosis in rapidly dividing cancer cells. Used for Metastatic colorectal cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}